FRIDAY, MAY 4, 2007
Registration opens at 10:00 am in Foyer of room. Lunch buffet available from 12:00 noon.
13:30 – 13:40 Welcome & Introduction – Eric van Cutsem, Matti Aapro
13:40 – 14:20 What is Angiogenesis in Relation to Cancer Developing Bevacizumab – Bob Kerbel
Session 1: Understanding Angiogenesis – Clinically Relevant Basic Data
14:20 – 15:00 The Role of VEGF in Cancer Development – Kari Alitalo 15:00 – 15:30 Do We Know the Molecular Markers That Help Us to Determine Who Benefits from Angiogenesis Inhibitors? – Emile Voest
15:30 – 16:00 Coffee Break
Session 2: Angiogenesis – Perspectives for Surgical and Radiation Oncology
16:10 – 16:35 Surgical Aspects When Treating with Anti-angiogenesis Agents – Oliver Stöltzing 16:35 – 17:00 Imaging and Angiogenesis – Pat Price 17:00 – 17:20 Can We Combine Angiogenesis Inhibitors with Radiotherapy? – Christopher Willett 17:20 – 17:30 Summary and Closure for the Day
20:00 Buses depart from hotel lobby to Course Dinner
SATURDAY, MAY 5, 2007
Session 3: Clinical Usage in Colorectal and Breast Cancer
08:30 – 09:00 Clinical Management of Anti-Angiogenesis Drugs – Herbert Pinedo 09:00 – 09:45 The Role of Anti-Angiogenesis Agents in the Treatment of Colorectal Cancer - Antonio Llombart 09:45 – 10:30 The Role of Anti-Angiogenesis Agents in the Treatment of Breast Cancer - Eric Van Cutsem
10:30 – 11:00 Coffee Break
Session 4: Clinical Usage in Lung Cancer and Other Cancers
11:00 – 11:45 The Role of Anti-Angiogenesis Agents in the Treatment of NSCLC – Enriqueta Felip 11:45 – 12:10 Anti-Angiogenesis in Prostate Cancer – What is New? – Joaquim Bellmunt 12:10 – 12:30 The Role of Anti-Angiogenesis Agents in Pancreatic Cancer – Michel Ducreux 12:30 – 12:50 Positioning Anti-Angiogenic Drugs in Renal Cell Carcinoma – Ahmad Awada 12:50 – 13:10 Gastric Cancer – How to Position Anti-Angiogenic Drugs – Josep Tabernero 13:10 – 13:30 Learning Assessments: 13:30 – 14:30 Lunch buffet and certificate delivery
